Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Entrectinib has received FDA’s orphan drug and rare pediatric disease designations for the treatment of neuroblastoma.

Ignyta’s Neuroblastoma Treatment Receives Orphan Drug Designation

The Cell Therapy Catapult, a UK non-profit center for advancing cell and gene therapies, will manage the manufacturing center, which will be used for late-phase clinical trials and commercial supply.

Cell Therapy Manufacturing Center to be Built in UK

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA has scheduled a public meeting in early January to assess and weigh data on the first United States application for a biosimilar therapy.

Biosimilar Development Moves Forward at FDA

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

FDA funded projects at Rutgers' C-SOPS and at UMass Lowell to develop flow-sheet model algorithms for use in risk assessment, and start-up company Continuus Pharmaceuticals is making progress on their integrated system.

Development Progresses in Continuous Solid-Dosage Manufacturing

Baxter announced that it had entered into an agreement to sell its Vero cell technology and related assets to Nanotherapeutics.

Baxter Enters Agreement to Sell Vero Cell Vaccines Platform

The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts.

Ebola R&D Gets Big Boosts

US Department of Health and Human Services announced a declaration to provide immunity to legal claims made in the US in relation to three investigational Ebola vaccines.

Legal Immunity Offered to Makers of Ebola Vaccines in the US

On December 8, Pfizer announced that it will establish a research program in gene therapy, and collaborate with Spark Therapeutics in Philadelphia, to develop potential gene therapy treatments for hemophilia.

Pfizer to Intensify AAV Vector Research in Gene Therapy for Hemophilia

Agnes Shanley is senior editor of Pharmaceutical Technology.

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.

Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

The final article of this series will look at the last two steps of the PharmaCare seven-step process?Lubricate and Store.